Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGORA-1 / ALFA 2100: gilteritinib plus gemtuzumab ozogamicin/cytarabine for relapsed or refractory FLT3-mutated acute myeloid leukemia
2023-504176-25-00Phase 2Authorised
- Sponsor
- Centre Antoine Lacassagne
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gilteritinib, gemtuzumab ozogamicin and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Centre Antoine Lacassagne. Primary endpoints: Dose-limiting toxicities and Event-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
gilteritinibgemtuzumab ozogamicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-504176-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504176-25-00.